#USA #New York #Class Action #Gross Law Firm #Capricor Therapeutics

Capricor Therapeutics Class Action Suit Overview

The Gross Law Firm recently announced a class action lawsuit aimed at recovering funds for shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) who might have faced financial losses due to allegedly deceptive business practices. All investors who purchased shares between December 17, 2025, and July 29, 2026, are encouraged to come forward and register their interest in being part of this legal action.

Background of the Case

Several complaints emerged throughout the trading period, alleging that Capricor Therapeutics made significant misrepresentations while failing to disclose crucial information that impacted the company's stock performance. Specifically, it is claimed that the organization adjusted the pre-specified statistical analysis plan related to Deramiocel, the lead product candidate, without appropriate FDA agreements. This situation heightened concerns regarding the product’s potential efficacy and regulatory approval for treating Duchenne muscular dystrophy.

In essence, the Gross Law Firm has positioned itself to protect shareholders' rights, emphasizing that any misleading statements made by Capricor resulted in artificially inflated stock prices that ultimately led to investor losses. Those affected are urged to seek out recovery through this class action suit, ensuring that corporate accountability is upheld.

What Shareholders Should Know

Shareholders have until September 28, 2026, to register for participation in this lawsuit. It’s essential for individuals to act quickly; joining the class action is free of charge and comes with no obligation. Once registered, shareholders will benefit from portfolio monitoring software which provides regular updates about case developments and overall status. The Gross Law Firm is committed to ensuring that all interested individuals have access to the resources necessary to understand their rights and possible recovery options.

Why Choose The Gross Law Firm?

The Gross Law Firm boasts a solid track record in navigating class action lawsuits across various industries. Their dedication lies in supporting the rights of investors who have lost money due to fraud and misrepresentation. Their mission is to help build a more accountable environment among corporations and to ensure that investor interests are not sidestepped. Their commitment speaks volumes as they tackle significant cases reflecting misleading corporate practices head-on.

Next Steps

To participate in the class action suit, shareholders are encouraged to visit this link to submit necessary information. This will formally initiate their involvement in the ongoing legal proceedings and ensure they are updated throughout the process.

The Gross Law Firm is well-equipped with experience and expertise dedicated to protecting the rights of shareholders. If you have faced losses with Capricor Therapeutics, this could be an essential step toward seeking justice.

Contact Information

For further inquiries, interested shareholders can contact The Gross Law Firm directly via:

• - Email: [email protected]
• - Phone: (646) 453-8903
• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018

This class action could prove vital for affected shareholders anxious to recoup losses, making it a critical moment for Capricor's investors. Time is of the essence, and proactive measures can lead to financial recovery and accountability.